Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Manal Tawashi"'
Autor:
Song Mu, Borje Darpo, Zhiyu Tang, William Novotny, Manal Tawashi, Hongqi Xue, Michael Willett, Leo Lin, Sri Sahasranaman, Ying C. Ou
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 5, Pp 923-931 (2020)
This thorough QT (TQT) study evaluated the effect of zanubrutinib on electrocardiogram (ECG) parameters by using concentration‐QTc (C‐QTc) analysis as the primary analysis for this study. Part A of the study determined the safety and tolerability
Externí odkaz:
https://doaj.org/article/e0ea160c88114e70927aa41ba7867992
Autor:
William Novotny, Zhiyu Tang, Srikumar Sahasranaman, Ying C. Ou, Ta-Kai Li, Hugh A Coleman, Manal Tawashi
Publikováno v:
British Journal of Clinical Pharmacology
Aim This study aims to assess the potential effects of zanubrutinib on the activity of cytochrome P450 (CYP) enzymes and drug transporter proteins using a cocktail probe approach. Methods Patients received single oral doses of probe drugs alone and a
Autor:
Amita Patnaik, Shirish Gadgeel, Kyriakos P. Papadopoulos, Drew W. Rasco, Naomi B. Haas, Hirak Der-Torossian, Demiana Faltaos, Diane Potvin, Vanessa Tassell, Manal Tawashi, Richard Chao, Peter J. O’Dwyer
Publikováno v:
Targeted oncology. 17(2)
Oncogenic drivers in solid tumors include aberrant activation of mesenchymal epithelial transition factor (MET) and AXL.This study investigated the safety and antitumor activity of glesatinib, a multitargeted receptor tyrosine kinase inhibitor that i
Publikováno v:
Journal of Ophthalmology and Research.
Autor:
Amita Patnaik, Shirish Gadgeel, Kyriakos P. Papadopoulos, Drew W. Rasco, Naomi B. Haas, Hirak Der-Torossian, Demiana Faltaos, Diane Potvin, Vanessa Tassell, Manal Tawashi, Richard Chao, Peter J. O’Dwyer
Publikováno v:
Targeted Oncology. 17:139-139
Autor:
William Novotny, Manal Tawashi, Ying C. Ou, Michael Willett, Leo Lin, Zhiyu Tang, Hongqi Xue, Sri Sahasranaman, Borje Darpo, Song Mu
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 13, Iss 5, Pp 923-931 (2020)
Clinical and Translational Science, Vol 13, Iss 5, Pp 923-931 (2020)
This thorough QT (TQT) study evaluated the effect of zanubrutinib on electrocardiogram (ECG) parameters by using concentration‐QTc (C‐QTc) analysis as the primary analysis for this study. Part A of the study determined the safety and tolerability
Autor:
Ying C. Ou, Zhiyu Tang, Thomas Marbury, Ta Kai Li, Manal Tawashi, Richard A. Preston, Srikumar Sahasranaman, William Novotny
Publikováno v:
Leukemialymphoma. 61(6)
The pharmacokinetics and safety of single-dose zanubrutinib (80 mg) were assessed in subjects with mild, moderate, and severe hepatic impairment (n = 6 each, Child–Pugh class A, B, and C) relative ...
Autor:
Raquel Izumi, S Devereux, Fanny Krantz, William G. Wierda, Manal Tawashi, Ahmed Hamdy, Deborah M. Stephens, Maria Fardis, Diana Mittag, Richard R. Furman, Jeffrey A. Jones, Priti Patel, Susan O'Brien, Peter Hillmen, John C. Byrd, Jennifer R. Brown, Wayne Rothbaum, Min Hui Wang
Publikováno v:
Journal of Clinical Oncology. 34:7521-7521
7521Background: Btk is a kinase involved in B-cell receptor signaling and a critical therapeutic target in CLL. Acalabrutinib—an irreversible, selective Btk inhibitor has demonstrated clinical effi...
Autor:
Kyri Papadopoulos, Manal Tawashi, Marielle Fournel, C. Maroun, Peter O'Dwyer, Anthony W. Tolcher, Amita Patnaik, J. Besterman, R.W. Humphrey, Muralidhar Beeram
Publikováno v:
Annals of Oncology. 23:ix169
Background MGCD265, a multikinase inhibitor with nM IC50 against Met, VEGFR 1, 2 and 3, Tie-2 and Ron, has been shown in preclinical models to possess broad antitumor effects. A phase I study was undertaken to assess therapy with MGCD265 and docetaxe
Autor:
Peter J. O'Dwyer, K. Harlacker, Ursina R. Teitelbaum, Marielle Fournel, Christiane R. Maroun, Jeffrey M. Besterman, Drew W. Rasco, James Wang, Manal Tawashi, M. Mehran, Lon Smith, Muralidhar Beeram, Anthony W. Tolcher, Michel Drouin, Kyriakos P. Papadopoulos, Andre Karam, Davendra Sohal, Amita Patnaik
Publikováno v:
Journal of Clinical Oncology. 30:e13602-e13602
e13602 Background: MGCD265 is a multi-target oral tyrosine kinase receptor inhibitor that targets Met (wild type and clinically-relevant Met mutants), VEGFRs 1, 2, 3, Tie and Ron. Combining Met and EGFR inhibitors has been shown to be synergistic and